Cosmos Health Inc. (NASDAQ: COSM) has entered an exclusive distribution agreement with Innova Healthcare to market its Sky Premium Life supplements across Saudi Arabia. The deal includes an initial purchase order of 126,000 units and grants Innova sole rights for an initial five-year period.

The agreement positions Cosmos Health to access one of the Kingdom’s largest pharmacy networks, comprising more than 250 outlets across 12 cities and villages. Innova will handle product registration, logistics, and sales through pharmacies, retail shops, and online platforms.

Deal Structure and Volume Expectations

Under the terms of the contract, Innova serves as the sole distributor for the Sky Premium Life range. The initial term is five years, with an option to renew for another five years. Innova also holds a first right of refusal to distribute new products developed or acquired by Cosmos Health during this period.

Cosmos Health expects orders to exceed 5 million units over the initial five-year term. This projection assumes current market conditions and the expansion of Innova’s retail network, which plans to grow beyond 500 pharmacies.

Market Context and Partner Profile

Saudi Arabia represents the largest healthcare market in the Gulf Cooperation Council. Grand View Research estimates the Saudi nutraceuticals market at approximately $3.26 billion in 2024, forecasting growth to $5.96 billion by 2033 at a compound annual growth rate of 6.9%.

Innova Healthcare, founded in 1994, operates under multiple banners including Innova Pharmacies and Health House. It is majority-owned by Alkhabeer Capital, which manages SAR 9.6 billion (approximately $2.5 billion) in assets. Other shareholders include Tamer Group and Cigalah Group, each holding a 12.5% stake.

Beyond its own stores, Innova Distribution supplies major retailers such as Amazon, noon, Boots, Nahdi, and Al-Dawaa. Its three Riyadh warehouses handle over 236 million units annually.

What the Numbers Show

The initial purchase order of 126,000 units represents approximately 2.5% of the total expected volume of 5 million units over the five-year term. This suggests that the majority of revenue realization from this deal is dependent on future execution and network expansion rather than immediate front-loaded sales.

Cosmos Health Inc. (NASDAQ: COSM) reported record financial results for the second quarter and first half of 2026, marking a significant milestone with an adjusted annualized revenue run-rate exceeding $75 million. The Chicago-based healthcare group recorded quarterly revenue of $18.99 million, a 28.8% increase from $14.75 million in the same period last year, and first-half revenue of $36.91 million, up 29.7% from $28.46 million in the prior-year period.

While the company continued to report a GAAP net loss, operational metrics showed marked improvement. Adjusted gross profit reached $1.84 million in Q2 2026, up 58.4% year-over-year, with adjusted gross margin expanding 165 basis points to 9.54%. Adjusted EBITDA improved to a loss of $1.13 million from a loss of $1.31 million in Q2 2025, reflecting operating leverage as expenses grew at roughly half the rate of revenue.

Financial Performance

The company’s top-line growth was driven by higher sales volumes across all core segments, including Decahedron’s near-doubling of revenue in the United Kingdom and Cana Laboratories building its contract manufacturing orderbook to over 25 million units. However, the GAAP net loss widened to $6.09 million in Q2 2026 from $2.83 million in Q2 2025, primarily due to $2.65 million in non-cash charges related to fair value adjustments on financing arrangements.

For the first half, total operating expenses were $8.00 million, up 19.6%, which remained well below the 29.7% revenue growth rate. Salaries and wages declined 0.7% year-over-year in Q2 despite significant revenue expansion, demonstrating positive operating leverage.

Balance Sheet and Capital Structure

Cosmos Health strengthened its capital structure during the first half of 2026. Total liabilities decreased by $6.27 million, or 13.3%, to $40.79 million as of June 30, 2026, from $47.05 million at year-end 2025. Conversely, total stockholders' equity increased by $2.25 million, or 12.2%, to $20.67 million. The liabilities-to-assets ratio improved by 550 basis points to 66.4%.

Liquid assets totaled $4.15 million, comprising cash and cash equivalents of $2.45 million and digital assets and marketable securities of $1.70 million. The company also initiated a share repurchase program of up to $5.0 million on June 26, 2026, having repurchased 5,112,000 shares for approximately $1.11 million as of the reporting date.

What the Numbers Show

The divergence between the widening GAAP net loss and the improving adjusted EBITDA highlights that the primary driver of the bottom-line deterioration is non-operational. Specifically, the $2.65 million in non-cash fair value adjustments on financing arrangements accounts for a substantial portion of the $6.09 million net loss. Excluding these items, the core business is demonstrating improved profitability, evidenced by the 58.4% surge in adjusted gross profit and the reduction in adjusted EBITDA losses, suggesting that operational efficiencies are beginning to translate into better unit economics despite the accounting noise from financing structures.